Somatotropin Penetration Testing from Formulations Applied Topically to the Skin
Growth hormone (somatotropin—STH) deficiency therapy requires daily injections of recombinant human growth hormone. The FDA approved treatment with STH with one dose per week for the first time in 2021. However, injectable drug application is accompanied by numerous inconveniences. Therefore, an att...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/13/4/2588 |